Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2016 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, 2016
Slide 1: Agilent Technologies Q3'16 Results Presentation
Agilent Technologies Q3’16 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, growth opportunities, customer service and innovation plans, new product introduction
Slide 3: Agilent Results Q3'16
Agilent Results Q3'16 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q3'16 Financial Metrics Q3'16 Headlines • Revenues: $1.044B, +3% y/y core(1)(2),+3% • Core revenue growth of 3% and EPS above the high reported (-0.7% FX, +0.6% M&A/NMR). Growth end of guidanc
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Mixed core revenue growth across regions with for Analytical Laboratories strength in Asia. Q3 a tough compare - start up issues last year in US logistics center resulted in one-time revenue shift from Q2’15 to Q3’15. Foo
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Core revenue growth led by Pharma, Food Consumables and Services and Environmental markets, continued expansion in Asia, and strength in LC Columns, Lab Supplies, and Contract Services. • Operating Margin in the quarter was 22.7%(1)(2), up 10 bps
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Solid growth across all businesses led Nucleic Acid Manufacturing by target enrichment, companion diagnostics, and nucleic acid solutions. Strength in Asia and North America. • Operating Margin for the quarter was 18.8%(1)(2), +200 bps
Slide 7: Growth in a $45B Market – Q3'16 Results by End Market
Growth in a $45B Market – Q3'16 Results by End Market Solid core growth led again by Food and Pharma, partially offset by continued soft Chemical/Energy Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q3'16 revenues: +3% y/y on core(2) basis Pharma & Biotech: Up 10% on techno
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus • Operating Margin up year-over-year – 6th consecutive quarter • Freezing U.S. defined benefit retirement plan • Consolidation of Finance systems o
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively expand operating margins from 18.8% (1) in FY14 to 22% by FY17 •
Slide 10: Q4'16 and FY16 Guidance and Forward-looking Considerations
Q4’16 and FY16 Guidance and Forward-looking Considerations Based on July 29, 2016 Exchange Rates FY16 FY16 Guidance FY15 Guidance at • Revenue: $4.14B - $4.16B: growth at mid-point 4.5% core(4), 2.8% Actual (2) mid-point reported (1) (0% NMR/M&A, -1.7% FX) (1)(2) • Operating Margin: 20.1% at mid-poi